Robert J. Marlowe

966 total citations
30 papers, 671 citations indexed

About

Robert J. Marlowe is a scholar working on Radiology, Nuclear Medicine and Imaging, Endocrinology, Diabetes and Metabolism and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Robert J. Marlowe has authored 30 papers receiving a total of 671 indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Radiology, Nuclear Medicine and Imaging, 16 papers in Endocrinology, Diabetes and Metabolism and 11 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Robert J. Marlowe's work include Thyroid Cancer Diagnosis and Treatment (16 papers), Medical Imaging Techniques and Applications (8 papers) and Radiopharmaceutical Chemistry and Applications (7 papers). Robert J. Marlowe is often cited by papers focused on Thyroid Cancer Diagnosis and Treatment (16 papers), Medical Imaging Techniques and Applications (8 papers) and Radiopharmaceutical Chemistry and Applications (7 papers). Robert J. Marlowe collaborates with scholars based in Germany, United States and Switzerland. Robert J. Marlowe's co-authors include Lutz S. Freudenberg, Walter Jentzen, T. Petrich, A. Bockisch, Samer Ezziddin, Fadi Khreish, Florian Rosar, Philipp Schüetz, Christoph Reiners and Beat Müeller and has published in prestigious journals such as Nature Medicine, The Journal of Clinical Endocrinology & Metabolism and Scientific Reports.

In The Last Decade

Robert J. Marlowe

29 papers receiving 662 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Robert J. Marlowe Germany	15	332	327	190	151	118	30	671
Thomas Grüning Germany	11	138 0.4×	174 0.5×	108 0.6×	51 0.3×	31 0.3×	31	510
H. Adams United Kingdom	13	212 0.6×	107 0.3×	186 1.0×	100 0.7×	36 0.3×	27	542
J. Mayo United States	6	137 0.4×	132 0.4×	233 1.2×	160 1.1×	24 0.2×	12	468
Anni Morsing Denmark	11	106 0.3×	201 0.6×	139 0.7×	56 0.4×	118 1.0×	15	439
Petra Petranović Ovčariček Switzerland	13	317 1.0×	120 0.4×	84 0.4×	143 0.9×	52 0.4×	43	572
Venanzio Porziella Italy	15	92 0.3×	83 0.3×	460 2.4×	259 1.7×	107 0.9×	70	777
M. G. Stabin United States	12	52 0.2×	241 0.7×	208 1.1×	146 1.0×	36 0.3×	18	516
Frank Atkins United States	13	441 1.3×	318 1.0×	69 0.4×	231 1.5×	64 0.5×	25	692
Anna Aronova United States	14	115 0.3×	65 0.2×	349 1.8×	269 1.8×	25 0.2×	26	772
Davide Leni Italy	14	148 0.4×	108 0.3×	88 0.5×	111 0.7×	36 0.3×	35	430

Countries citing papers authored by Robert J. Marlowe

Since Specialization

Citations

This map shows the geographic impact of Robert J. Marlowe's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Robert J. Marlowe with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Robert J. Marlowe more than expected).

Fields of papers citing papers by Robert J. Marlowe

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Robert J. Marlowe. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Robert J. Marlowe. The network helps show where Robert J. Marlowe may publish in the future.

Co-authorship network of co-authors of Robert J. Marlowe

This figure shows the co-authorship network connecting the top 25 collaborators of Robert J. Marlowe. A scholar is included among the top collaborators of Robert J. Marlowe based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Robert J. Marlowe. Robert J. Marlowe is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Rosar, Florian, Caroline Burgard, Robert J. Marlowe, et al.. (2024). Dual FDG/PSMA PET imaging to predict lesion-based progression of mCRPC during PSMA-RLT. Scientific Reports. 14(1). 11271–11271. 6 indexed citations

Burgard, Caroline, Florian Rosar, Fadi Khreish, et al.. (2024). Outstanding increase in tumor-to-background ratio over time allows tumor localization by [89Zr]Zr-PSMA-617 PET/CT in early biochemical recurrence of prostate cancer. Cancer Imaging. 24(1). 132–132. 2 indexed citations

Rosar, Florian, Caroline Burgard, Fadi Khreish, et al.. (2024). [89Zr]Zr-PSMA-617 PET/CT characterization of indeterminate [68Ga]Ga-PSMA-11 PET/CT findings in patients with biochemical recurrence of prostate cancer: lesion-based analysis. Cancer Imaging. 24(1). 27–27. 1 indexed citations

Rosar, Florian, Fadi Khreish, Robert J. Marlowe, et al.. (2023). Detection efficacy of [89Zr]Zr-PSMA-617 PET/CT in [68Ga]Ga-PSMA-11 PET/CT-negative biochemical recurrence of prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging. 50(9). 2899–2909. 13 indexed citations

Burgard, Caroline, Florian Rosar, Robert J. Marlowe, et al.. (2023). Tumor Sink Effect with Prostate-Specific Membrane Antigen-Targeted Theranostics in Patients with Metastatic Castration-Resistant Prostate Cancer: Intra-Individual Evaluations. Cancers. 15(9). 2592–2592. 12 indexed citations

Burgard, Caroline, Manuela A. Hoffmann, Hans‐Georg Buchholz, et al.. (2023). Detection Efficacy of 68Ga-PSMA-11 PET/CT in Biochemical Recurrence of Prostate Cancer with Very Low PSA Levels: A 7-Year, Two-Center “Real-World” Experience. Cancers. 15(5). 1376–1376. 21 indexed citations

Burchert, Andreas, Glenn Flux, Robert J. Marlowe, et al.. (2022). Second primary malignancies induced by radioactive iodine treatment of differentiated thyroid carcinoma — a critical review and evaluation of the existing evidence. European Journal of Nuclear Medicine and Molecular Imaging. 49(9). 3247–3256. 14 indexed citations

Frangos, Savvas, et al.. (2016). Acknowledging gray areas: 2015 vs. 2009 American Thyroid Association differentiated thyroid cancer guidelines on ablating putatively low-intermediate-risk patients. European Journal of Nuclear Medicine and Molecular Imaging. 44(2). 185–189. 14 indexed citations

Frangos, Savvas, et al.. (2015). Difficulties in deciding whether to ablate patients with putatively “low–intermediate-risk” differentiated thyroid carcinoma: do guidelines mainly apply in the centres that produce them? Results of a retrospective, two-centre quality assurance study. European Journal of Nuclear Medicine and Molecular Imaging. 42(13). 2045–2055. 13 indexed citations

10.

Schüetz, Philipp, Robert J. Marlowe, & Beat Müeller. (2014). The prognostic blood biomarker proadrenomedullin for outcome prediction in patients with chronic obstructive pulmonary disease (COPD): a qualitative clinical review. Clinical Chemistry and Laboratory Medicine (CCLM). 53(4). 521–39. 24 indexed citations

11.

Grolimund, Eva, Alexander Kutz, Robert J. Marlowe, et al.. (2014). Long-term Prognosis in COPD Exacerbation: Role of Biomarkers, Clinical Variables and Exacerbation Type. COPD Journal of Chronic Obstructive Pulmonary Disease. 12(3). 300–310. 36 indexed citations

12.

Schüetz, Philipp, Alexander Kutz, Eva Grolimund, et al.. (2014). Excluding infection through procalcitonin testing improves outcomes of congestive heart failure patients presenting with acute respiratory symptoms: Results from the randomized ProHOSP trial. International Journal of Cardiology. 175(3). 464–472. 52 indexed citations

13.

Opfermann, Thomas, et al.. (2013). Low-Activity 124I-PET/Low-Dose CT Versus 99mTc-Pertechnetate Planar Scintigraphy or 99mTc-Pertechnetate Single-Photon Emission Computed Tomography of the Thyroid. Clinical Nuclear Medicine. 38(10). 770–777. 14 indexed citations

14.

Pitoia, Fabián, Robert J. Marlowe, Erika Abelleira, et al.. (2012). Radioiodine Thyroid Remnant Ablation after Recombinant Human Thyrotropin or Thyroid Hormone Withdrawal in Patients with High-Risk Differentiated Thyroid Cancer. Journal of Thyroid Research. 2012. 1–8. 12 indexed citations

15.

Casas, Juan Antonio Vallejo, et al.. (2011). Treatment room length-of-stay and patient throughput with radioiodine thyroid remnant ablation in differentiated thyroid cancer. Nuclear Medicine Communications. 32(9). 840–846. 9 indexed citations

16.

Freudenberg, Lutz S., Walter Jentzen, T. Petrich, et al.. (2010). Lesion dose in differentiated thyroid carcinoma metastases after rhTSH or thyroid hormone withdrawal: 124I PET/CT dosimetric comparisons. European Journal of Nuclear Medicine and Molecular Imaging. 37(12). 2267–2276. 47 indexed citations

17.

Freudenberg, Lutz S., et al.. (2010). Lymphatic Mapping Using SPECT/CT in Vulvar Carcinoma. Clinical Nuclear Medicine. 35(12). 950–952. 10 indexed citations

18.

Freudenberg, Lutz S., Cornelia Frömke, T. Petrich, et al.. (2009). Thyroid Remnant Dose: ¹²⁴I-PET/CT Dosimetric Comparison of rhTSH versus Thyroid Hormone Withholding Before Radioiodine Remnant Ablation in Differentiated Thyroid Cancer. Experimental and Clinical Endocrinology & Diabetes. 118(7). 393–399. 18 indexed citations

19.

Verburg, Frederik A., Marcel P. M. Stokkel, Uwe Mäder, et al.. (2009). No survival difference after successful 131I ablation between patients with initially low-risk and high-risk differentiated thyroid cancer. European Journal of Nuclear Medicine and Molecular Imaging. 37(2). 276–283. 83 indexed citations

20.

Freudenberg, Lutz S., et al.. (2007). 124-Iodine Positron Emission Tomography/Computed Tomography Dosimetry in Pediatric Patients with Differentiated Thyroid Cancer. Experimental and Clinical Endocrinology & Diabetes. 115(10). 690–693. 16 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact